Rigel plans to launch Veppanu in August after antitrust clearance for a deal with Arvinas and Pfizer. The $70 million upfront payment and up to $320 million milestones are now active.
Alpha Score of 51 reflects moderate overall profile with weak momentum, strong value, weak quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.
Rigel Pharmaceuticals received U.S. antitrust clearance for its licensing deal covering the drug Veppanu, the company said Monday. The waiting period under the Hart-Scott-Rodino Act expired without a challenge.
The deal became active immediately. Rigel will pay Arvinas and Pfizer $70 million upfront. The agreement includes milestone payments of up to $320 million, tied to regulatory and commercial benchmarks.
Rigel plans to launch Veppanu in August. The drug has received FDA approval, the company said, though it did not disclose the specific indication. Arvinas and Pfizer had been developing Veppanu before the licensing arrangement. Rigel will take over manufacturing and sales.
The $70 million payment is a near-term win for Arvinas and Pfizer. Both companies have been investing in early-stage drug development. Arvinas, a biotech focused on protein degradation, has a pipeline but limited revenue from marketed products. Pfizer, one of the world's largest drugmakers, gains another asset that could generate royalties down the line.
For Rigel, the deal adds a commercial-stage product to its portfolio. The company sells Tavalisse for immune thrombocytopenia and Rezlidhia for acute myeloid leukemia. Adding Veppanu broadens its commercial footprint.
The antitrust clearance removes a key risk factor for the deal. Licensing agreements of this size can trigger a second request from the Federal Trade Commission. The fact that the waiting period ended without a challenge suggests regulators saw no competitive concerns.
Rigel shares have been volatile in recent months as investors awaited the deal's closure. The clearance removes that overhang. The company now faces the challenge of launching into a competitive market.
The milestone payments are structured around sales thresholds and regulatory milestones beyond the initial launch. If Veppanu hits those targets, Arvinas and Pfizer could receive additional payments over the next few years.
Rigel expects to discuss launch plans and revenue projections in its second-quarter earnings call in early August.
Prepared with AlphaScala editorial tooling from the source reporting linked above. Indexable analysis may include a cited Alpha Score value. Publishing checks screen each story before release. Educational coverage, not personalized advice.